Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects

Marek Samec1, Alena Liskova1, Lenka Koklesova1

  • 1Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovakia.

Cancers
|July 2, 2021
PubMed

Insights

Melatonin, a natural hormone, demonstrates significant anticancer effects by regulating key cancer metabolism pathways. Further research into melatonin

Area of Science:

  • Oncology
  • Metabolic pathways
  • Hormone research

Background:

  • Metabolic reprogramming is crucial for cancer development.
  • Melatonin (N-acetyl-5-methoxytryptamine) is a hormone with known anti-tumor properties.
  • Melatonin influences circadian rhythms and possesses antioxidant and anti-inflammatory effects.

Purpose of the Study:

  • To investigate the role of melatonin in regulating cancer metabolism.
  • To explore melatonin's impact on key metabolic pathways in cancer cells.
  • To assess melatonin's potential as an anti-cancer therapeutic agent.

Main Methods:

  • Analysis of melatonin's effects on aerobic glycolysis, gluconeogenesis, and the pentose phosphate pathway (PPP).
  • Evaluation of melatonin's influence on glucose transporter (GLUT) expression and glucose-6-phosphate dehydrogenase (G6PDH) activity.
  • Examination of melatonin's modulation of cancer-related factors like HIF-1 and p53.

Main Results:

  • Melatonin significantly impacts key components of cancer cell metabolism.
  • Melatonin treatment alters glucose metabolism, including GLUT expression and G6PDH activity.
  • Melatonin effectively modulates critical cancer development players such as HIF-1 and p53.

Conclusions:

  • Melatonin exhibits notable anti-cancer effects across malignancy initiation, progression, and metastasis.
  • Melatonin's regulation of cancer metabolism offers potential for innovative cancer prevention and therapy.
  • Further research on melatonin's metabolic impacts is crucial for developing targeted cancer treatments.

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
357
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
299
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K